Mein US Kumpel hat Antwort von der IR erhalten.
Thanks for reaching out to us. Naturally, where the stock price has gone today so far is not what we want to see either, we understand your frustration there.
There are a few things I would comment that hopefully can put your mind at ease a bit more:
Firstly, the analysts have not issued their reports yet, which they usually do later in the day (US time) or tomorrow morning. Their reports always an good objective opinion on the company (rather than just headlines, which is probably what most people are reacting to now), and it’s possible the market will respond to that.
As we mentioned today, our guidance for revenue is 60 – 65 million Euros for the full year. That is higher than all analysts estimated before today, and higher than the 20% growth guidance we gave at the end of last year (before we knew COVID would happen).
Our Pharma discussions are stronger than ever at the moment, and the six new partnerships we signed are a good evidence of that.
As mentioned, we anticipate our weekly order intake volume getting back to pre-pandemic levels in Q4
And you would have seen the number of COVID tests we performed at Frankfurt Airport in July and especially August, and have of course also opened testing facilities at Hamburg airport and Dusseldorf airport.
Keeping all those things in mind, those are all reasons to be optimistic for the rest of the year. And of course, our vision of the future of Centogene has not changed at all going into 2021 and beyond.
As for getting on investors radar, we work very hard to do so with our earnings calls, roadshows, and further investor outreach. But also keep in mind the company has only been listed for less than a year, and building name recognition and growing the company takes time.
I hope I have sufficiently addressed your concerns and thanks for being an engaged investor in our company. If there is anything else I can address, do let me know.